vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与SHOE CARNIVAL INC（SCVL）财务数据对比。点击上方公司名可切换其他公司
SHOE CARNIVAL INC的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.9倍（$297.2M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 4.9%，领先29.6%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -3.2%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $19.7M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 3.0%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Shoe Carnival Inc是一家美国家庭鞋类零售商，目前在美国中西部、南部、东南部地区以及波多黎各共开设了429家门店。该公司由大卫·拉塞尔于1978年创立，截至2025年，其总部位于南卡罗来纳州福特米尔。
CPRX vs SCVL — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $297.2M |
| 净利润 | $52.7M | $14.6M |
| 毛利率 | 82.9% | 37.6% |
| 营业利润率 | 40.5% | 6.3% |
| 净利率 | 34.5% | 4.9% |
| 营收同比 | 7.6% | -3.2% |
| 净利润同比 | -5.8% | -23.9% |
| 每股收益（稀释后） | $0.40 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $297.2M | ||
| Q3 25 | $148.4M | $306.4M | ||
| Q2 25 | $146.6M | $277.7M | ||
| Q1 25 | $141.4M | $262.9M | ||
| Q4 24 | $141.8M | $306.9M | ||
| Q3 24 | $128.7M | $332.7M | ||
| Q2 24 | $122.7M | $300.4M | ||
| Q1 24 | $98.5M | $280.2M |
| Q4 25 | $52.7M | $14.6M | ||
| Q3 25 | $52.8M | $19.2M | ||
| Q2 25 | $52.1M | $9.3M | ||
| Q1 25 | $56.7M | $14.7M | ||
| Q4 24 | $55.9M | $19.2M | ||
| Q3 24 | $43.9M | $22.6M | ||
| Q2 24 | $40.8M | $17.3M | ||
| Q1 24 | $23.3M | $15.5M |
| Q4 25 | 82.9% | 37.6% | ||
| Q3 25 | 84.7% | 38.8% | ||
| Q2 25 | 85.9% | 34.5% | ||
| Q1 25 | 87.3% | 34.9% | ||
| Q4 24 | 84.7% | 36.0% | ||
| Q3 24 | 85.0% | 36.1% | ||
| Q2 24 | 87.4% | 35.6% | ||
| Q1 24 | 87.3% | 35.6% |
| Q4 25 | 40.5% | 6.3% | ||
| Q3 25 | 44.7% | 8.2% | ||
| Q2 25 | 45.2% | 4.3% | ||
| Q1 25 | 44.8% | 5.3% | ||
| Q4 24 | 44.3% | 8.0% | ||
| Q3 24 | 39.6% | 9.0% | ||
| Q2 24 | 44.2% | 7.5% | ||
| Q1 24 | 27.5% | 7.1% |
| Q4 25 | 34.5% | 4.9% | ||
| Q3 25 | 35.6% | 6.3% | ||
| Q2 25 | 35.6% | 3.4% | ||
| Q1 25 | 40.1% | 5.6% | ||
| Q4 24 | 39.4% | 6.3% | ||
| Q3 24 | 34.1% | 6.8% | ||
| Q2 24 | 33.2% | 5.8% | ||
| Q1 24 | 23.6% | 5.5% |
| Q4 25 | $0.40 | $0.53 | ||
| Q3 25 | $0.42 | $0.70 | ||
| Q2 25 | $0.41 | $0.34 | ||
| Q1 25 | $0.45 | $0.53 | ||
| Q4 24 | $0.44 | $0.70 | ||
| Q3 24 | $0.35 | $0.82 | ||
| Q2 24 | $0.33 | $0.63 | ||
| Q1 24 | $0.19 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $107.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $683.2M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $107.7M | ||
| Q3 25 | $689.9M | $91.9M | ||
| Q2 25 | $652.8M | $93.0M | ||
| Q1 25 | $580.7M | $123.1M | ||
| Q4 24 | $517.6M | $91.1M | ||
| Q3 24 | $442.3M | $84.5M | ||
| Q2 24 | $375.7M | $69.5M | ||
| Q1 24 | $310.4M | $111.2M |
| Q4 25 | $954.3M | $683.2M | ||
| Q3 25 | $920.2M | $670.7M | ||
| Q2 25 | $856.0M | $653.6M | ||
| Q1 25 | $794.3M | $649.0M | ||
| Q4 24 | $727.6M | $635.7M | ||
| Q3 24 | $660.9M | $618.5M | ||
| Q2 24 | $608.7M | $597.8M | ||
| Q1 24 | $561.4M | $583.4M |
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $971.9M | $1.1B | ||
| Q1 25 | $908.9M | $1.1B | ||
| Q4 24 | $851.4M | $1.1B | ||
| Q3 24 | $772.0M | $1.1B | ||
| Q2 24 | $706.4M | $1.1B | ||
| Q1 24 | $646.7M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $33.6M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $19.7M |
| 自由现金流率自由现金流/营收 | 29.4% | 6.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.7% |
| 现金转化率经营现金流/净利润 | 0.85× | 2.30× |
| 过去12个月自由现金流最近4个季度 | — | $35.1M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $33.6M | ||
| Q3 25 | $32.4M | $13.3M | ||
| Q2 25 | $71.3M | $-9.6M | ||
| Q1 25 | $60.0M | $44.5M | ||
| Q4 24 | $70.9M | $17.3M | ||
| Q3 24 | $72.9M | $23.7M | ||
| Q2 24 | $64.1M | $17.1M | ||
| Q1 24 | $31.9M | $53.4M |
| Q4 25 | $44.9M | $19.7M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $71.3M | $-23.0M | ||
| Q1 25 | — | $36.2M | ||
| Q4 24 | $70.8M | $8.3M | ||
| Q3 24 | $72.6M | $18.2M | ||
| Q2 24 | $64.1M | $6.9M | ||
| Q1 24 | $31.7M | $40.7M |
| Q4 25 | 29.4% | 6.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 48.6% | -8.3% | ||
| Q1 25 | — | 13.8% | ||
| Q4 24 | 49.9% | 2.7% | ||
| Q3 24 | 56.4% | 5.5% | ||
| Q2 24 | 52.3% | 2.3% | ||
| Q1 24 | 32.2% | 14.5% |
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.8% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.1% | 3.0% | ||
| Q3 24 | 0.2% | 1.7% | ||
| Q2 24 | 0.0% | 3.4% | ||
| Q1 24 | 0.2% | 4.5% |
| Q4 25 | 0.85× | 2.30× | ||
| Q3 25 | 0.61× | 0.69× | ||
| Q2 25 | 1.37× | -1.03× | ||
| Q1 25 | 1.06× | 3.04× | ||
| Q4 24 | 1.27× | 0.90× | ||
| Q3 24 | 1.66× | 1.05× | ||
| Q2 24 | 1.57× | 0.99× | ||
| Q1 24 | 1.37× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
SCVL
暂无分部数据
